Ignite Creation Date:
2025-12-25 @ 1:24 AM
Ignite Modification Date:
2025-12-25 @ 11:34 PM
Study NCT ID:
NCT07168993
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-09-11
First Post:
2025-09-05
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, >6 to <30 mm in Diameter, Determined by LDCT.
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D004194', 'term': 'Disease'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'DIAGNOSTIC', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 2063}}, 'statusModule': {'overallStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2025-11-01', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-09', 'completionDateStruct': {'date': '2029-07-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-09-05', 'studyFirstSubmitDate': '2025-09-05', 'studyFirstSubmitQcDate': '2025-09-05', 'lastUpdatePostDateStruct': {'date': '2025-09-11', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2025-09-11', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2029-04-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Evaluate FlowPath Lung Test Detection of Early-Stage Lung Cancer in Sputum', 'timeFrame': 'From Baseline Sputum Sample provided by subject through 24 months follow up period.', 'description': 'Evaluate the clinical performance (positive percent agreement \\[PPA/sensitivity\\] and negative percent agreement \\[NPA/specificity\\]) of the FlowPath Lung test in predicting lung cancer from the sputum of high-risk individuals with lung nodules'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Lung Cancer', 'Diagnostic Test', 'Sputum Assay'], 'conditions': ['Lung Cancer (Diagnosis)']}, 'descriptionModule': {'briefSummary': 'Evaluate FlowPath Lung Diagnostic Test of Sputum Samples to Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, \\>6 to \\<30 mm in Diameter, Determined by LDCT.', 'detailedDescription': 'Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, \\>6 to \\<30 mm in Diameter, Determined by LDCT.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '50 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Is able to give signed informed consent and comply with study requirements.\n2. Is high risk for getting lung cancer:\n\n 1. ≥50 - 80 years of age.\n 2. current smoker with smoking history of at least 20 pack-years or current non-smoker with smoking history of at least 20 pack-years who quit smoking within the past 15 years.\n3. Has a \\>6 to \\<30 mm diameter lung nodule (found by lung cancer screening or found incidentally by CT scan) as determined by CT and is willing to provide a sputum sample for FlowPath Lung test within 6 weeks of the prestudy baseline CT scan.\n\n3a) Nodule is either new, increasing, or stable for ≤ 6 months. 3b) In cases where a person has multiple nodules as determined by CT scan, the subject's most suspicious nodule is \\>6 to \\<30 mm in diameter.\n\n4\\) Is willing to provide contact information to the study PI or the treating physician(s) who can release required medical information related to SOC follow-up.\n\nExclusion Criteria:\n\n1. Is unable to cough with sufficient exertion to produce a sputum sample (e.g., due to severe obstructive lung disease).\n2. The dominant nodule is ground glass or part solid as determined by CT scan.\n3. Has 5 or more nodules sized \\>4 mm.\n4. The nodule sized \\>6 to \\<30 mm in diameter is a distal (subsegmental) endobronchial nodule or a perifissural nodule.\n5. Is immunosuppressed.\n6. Has rheumatoid arthritis.\n7. Had lung cancer diagnosis in the past 5 years or any other cancer (other than non-melanoma skin cancer) in the past 2 years. A subject on long-term medications used for prevention of cancer, such as Tamoxifen for breast cancer, is not excluded.\n8. Has angina with minimal exertion.\n9. Is currently pregnant or planning on becoming pregnant during this study."}, 'identificationModule': {'nctId': 'NCT07168993', 'acronym': 'BA-004', 'briefTitle': 'Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, >6 to <30 mm in Diameter, Determined by LDCT.', 'organization': {'class': 'INDUSTRY', 'fullName': 'bioAffinity Technologies Inc.'}, 'officialTitle': 'Detection of Early-Stage Lung Cancer in Sputum Using Flow Cytometry and an Automated Analysis Pipeline', 'orgStudyIdInfo': {'id': 'BA-004'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Single', 'description': 'Diagnostic testing of sputum sample provided by subject', 'interventionNames': ['Other: Standard medical treatment']}], 'interventions': [{'name': 'Standard medical treatment', 'type': 'OTHER', 'otherNames': ['Standard of care follow up per institution'], 'description': 'Standard of care follow up per institution', 'armGroupLabels': ['Single']}, {'name': 'Standard medical treatment', 'type': 'OTHER', 'otherNames': ['Follow up SOC'], 'description': 'SOC per institution', 'armGroupLabels': ['Single']}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'bioAffinity Technologies Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}